Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: crospovidone; pregelatinised maize starch; povidone; purified water; microcrystalline cellulose; magnesium stearate; stearic acid - temporary relief of the following cold and flu symptoms: nasal congestion, sinus pain, runny nose, headache and body aches & pains. reduces fever

United States - English - NLM (National Library of Medicine)

clinical solutions wholesale, llc - clonazepam (unii: 5pe9fde8gb) (clonazepam - unii:5pe9fde8gb) - clonazepam tablets are useful alone or as an adjunct in the treatment of the lennox-gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. in patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets may be useful. some loss of effect may occur during the course of clonazepam treatment (see precautions: loss of effect ). clonazepam tablets are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in dsm-v. panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. the efficacy of clonazepam tablets was established in two 6 to 9 week trials in panic disorder patients whose diagnoses corresponded to the dsm-iiir category of panic disorder (see clinical pharmacology, clinical trials ). panic disorder (dsm-v) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. the effectiveness of clonazepam tablets in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. the physician who elects to use clonazepam tablets for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see dosage and administration ). clonazepam is contraindicated in patients with the following conditions: - history of sensitivity to benzodiazepines - clinical or biochemical evidence of significant liver disease - acute narrow angle glaucoma (it may be used in patients with open angle glaucoma who are - receiving appropriate therapy). clonazepam is a schedule iv controlled substance. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (e.g., convulsions, psychosis, hallucinations, behavioral disorder, mood changes, tremor, abdominal and muscle cramps) have occurred following abrupt discontinuance of clonazepam. the more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed (see dosage and administration ). addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving clonazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence. following the short-term treatment of patients with panic disorder in studies 1 and 2 (see clinical pharmacology, clinical trials ), patients were gradually withdrawn during a 7 week downward-titration (discontinuance) period. overall, the discontinuance period was associated with good tolerability and a very modest clinical deterioration, without evidence of a significant rebound phenomenon. however, there are not sufficient data from adequate and well-controlled long-term clonazepam studies in patients with panic disorder to accurately estimate the risks of withdrawal symptoms and dependence that may be associated with such use.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct850 - clinical chemistry hormone ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of clinical chemistry hormones in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct847 - clinical chemistry vitamin and mineral ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of vitamins and minerals in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct850 - clinical chemistry hormone ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of clinical chemistry hormones in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct845 - clinical chemistry tumour marker ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of specific tumour markers in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct974 - clinical chemistry-specific protein ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of proteins specific to clinical chemistry, in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct860 - clinical chemistry therapeutic drug monitoring ivds - ivds that are intended to be used in monitoring of therapeutic drug levels in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct974 - clinical chemistry-specific protein ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of proteins specific to clinical chemistry, in a clinical specimen.

Australia - English - Department of Health (Therapeutic Goods Administration)

ortho-clinical diagnostics australia pty ltd - ct869 - clinical chemistry autoimmune ivds - ivds that are intended to be used for the qualitative and/or quantitative determination of autoimmune markers in a clinical specimen.